B. Riley Issues Pessimistic Outlook for Abacus Life Earnings

Abacus Life, Inc. (NASDAQ:ABL) – Equities research analysts at B. Riley reduced their Q1 2025 earnings per share estimates for shares of Abacus Life in a report issued on Wednesday, April 9th. B. Riley analyst R. Binner now expects that the company will earn $0.14 per share for the quarter, down from their previous estimate of $0.15. B. Riley currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Abacus Life’s current full-year earnings is $0.62 per share. B. Riley also issued estimates for Abacus Life’s Q2 2025 earnings at $0.16 EPS and Q4 2025 earnings at $0.26 EPS.

Abacus Life (NASDAQ:ABL) last issued its earnings results on Thursday, March 27th. The company reported $0.16 EPS for the quarter, topping the consensus estimate of $0.13 by $0.03. The business had revenue of $33.21 million during the quarter, compared to the consensus estimate of $28.76 million. Abacus Life had a positive return on equity of 12.88% and a negative net margin of 11.65%.

Separately, Piper Sandler cut their target price on Abacus Life from $13.00 to $11.50 and set an “overweight” rating for the company in a research note on Tuesday. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Abacus Life has an average rating of “Buy” and an average target price of $14.00.

Abacus Life Stock Up 6.9 %

Shares of NASDAQ ABL opened at $7.10 on Thursday. Abacus Life has a 12 month low of $6.34 and a 12 month high of $12.50. The company has a current ratio of 1.29, a quick ratio of 1.29 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $687.66 million, a price-to-earnings ratio of -39.44 and a beta of 0.16. The business has a 50-day moving average of $7.50 and a 200-day moving average of $8.10.

Institutional Investors Weigh In On Abacus Life

Institutional investors have recently modified their holdings of the stock. Alyeska Investment Group L.P. boosted its position in shares of Abacus Life by 116.5% during the fourth quarter. Alyeska Investment Group L.P. now owns 2,540,790 shares of the company’s stock valued at $19,894,000 after buying an additional 1,367,210 shares during the last quarter. Royce & Associates LP raised its stake in Abacus Life by 339.9% during the 4th quarter. Royce & Associates LP now owns 1,306,431 shares of the company’s stock valued at $10,229,000 after purchasing an additional 1,009,431 shares during the period. Kennedy Capital Management LLC purchased a new position in Abacus Life during the 4th quarter valued at approximately $7,461,000. Monashee Investment Management LLC purchased a new position in Abacus Life during the 4th quarter valued at approximately $6,342,000. Finally, Mendon Capital Advisors Corp grew its holdings in Abacus Life by 137.1% during the 4th quarter. Mendon Capital Advisors Corp now owns 1,303,826 shares of the company’s stock valued at $10,209,000 after buying an additional 753,826 shares in the last quarter.

About Abacus Life

Abacus Life, Inc operates as an alternative asset manager specializing in life insurance products. It purchases life insurance policies from consumers seeking liquidity and manages policies over time via trading, holding, and/or servicing. The company was founded in 2004 and is based in Orlando, Florida.